Sky Investment Group LLC Sells 692 Shares of Johnson & Johnson (NYSE:JNJ)

Sky Investment Group LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 1.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 68,462 shares of the company’s stock after selling 692 shares during the quarter. Johnson & Johnson accounts for about 1.8% of Sky Investment Group LLC’s holdings, making the stock its 11th biggest holding. Sky Investment Group LLC’s holdings in Johnson & Johnson were worth $9,901,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wescott Financial Advisory Group LLC raised its holdings in Johnson & Johnson by 50.5% in the 2nd quarter. Wescott Financial Advisory Group LLC now owns 16,637 shares of the company’s stock worth $2,432,000 after purchasing an additional 5,581 shares in the last quarter. Zurich Insurance Group Ltd FI grew its position in shares of Johnson & Johnson by 366.6% in the 2nd quarter. Zurich Insurance Group Ltd FI now owns 145,105 shares of the company’s stock worth $21,209,000 after buying an additional 114,005 shares during the period. Fred Alger Management LLC grew its position in shares of Johnson & Johnson by 6.1% in the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after buying an additional 2,488 shares during the period. Toronto Dominion Bank grew its position in shares of Johnson & Johnson by 13.0% in the 2nd quarter. Toronto Dominion Bank now owns 1,197,314 shares of the company’s stock worth $174,999,000 after buying an additional 137,292 shares during the period. Finally, Trinity Legacy Partners LLC grew its position in shares of Johnson & Johnson by 5.7% in the 2nd quarter. Trinity Legacy Partners LLC now owns 31,616 shares of the company’s stock worth $4,621,000 after buying an additional 1,699 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

NYSE JNJ opened at $145.39 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market cap of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. The company’s 50 day moving average is $148.26 and its two-hundred day moving average is $156.12. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same quarter last year, the business earned $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on JNJ. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Bank of America cut their price objective on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday, January 17th. Finally, Barclays cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.